Name | FN-1501 |
Description | FN-1501 is a potent FLT3 and CDK inhibitor (IC50s: 2.47, 0.85, 1.96, and 0.28 nM for CDK2/cyclin A, CDK4/cyclin D1, CDK6/cyclin D1 and FLT3, respectively). FN-1501 also has anticancer activity. |
In vitro | FN-1501 displays potent inhibitory activity against several tumor cells, such as MGC803, RS4;11, MCF-7, HCT-116, and NCI-H82 (GI50s of 0.37 ± 0.04, 0.05 ± 0.01, 2.84 ± 0.25, 0.09 ± 0.04, 0.11 ± 0.02 nM, respectively)[1]. |
In vivo | FN-1501 shows potent antitumor activity and it also shows little cytotoxicity on normal lymphocyte cells (LD50: 185.67 mg/kg in ICR mice). FN-1501 (15. 30, or 40 mg/kg/d, i.v.) dose-dependently and obviously inhibits the growth of tumors in MV4-11-cell-inoculated-xenograft mice[1]. |
Storage | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice. |
Solubility Information | DMSO : 45 mg/mL (104.29 mM)
|
Keywords | FLT3 | Fms like tyrosine kinase 3 | Cluster of differentiation antigen 135 | CD135 | Cyclin dependent kinase | CDK | FN1501 | inhibit | Inhibitor | FN 1501 | FN-1501 |
Inhibitors Related | Ribociclib | Gilteritinib | Nintedanib | Sorafenib | Pexidartinib | Sorafenib tosylate | CASIN | Palbociclib | Sodium Oxamate | Abemaciclib | Dinaciclib | Abemaciclib methanesulfonate |
Related Compound Libraries | Bioactive Compound Library | Tyrosine Kinase Inhibitor Library | Kinase Inhibitor Library | Anti-Cancer Clinical Compound Library | Drug Repurposing Compound Library | Inhibitor Library | Anti-Aging Compound Library | Bioactive Compounds Library Max | Anti-Cancer Drug Library | Anti-Cancer Active Compound Library |